Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
AstraZeneca, daiichi Sankyo and FDA
AstraZeneca, Daiichi’s drug cleared for wider use in breast cancer patients in US
Astra is due to pay Daiichi US$175 million in milestones after the US approval, the companies said. Enhertu is cleared in the US and European Union for some breast cancer patients whose cancer spread after receiving treatment, or whose disease returned after surgery.
FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients
FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant efficacy in the DESTINY-Breast06 trial.
FDA Approves AstraZeneca, Daiichi Sankyo’s Enhertu for Unresectable or Metastatic Hormone Receptor-Positive, HER2-Low Breast Cancer
Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, HER2-low, or HER2-ultralow metastatic breast cancer.
AstraZeneca & Daiichi Sankyo’s Enhertu Approved by FDA for Treatment of Metastatic Breast Cancer
New approval brings the medicine to an earlier treatment setting and a broader patient population.
AstraZeneca Receives FDA Approval for Enhertu Breast Cancer Treatment
AstraZeneca received Food and Drug Administration approval for enhertu, its breast cancer treatment developed in partnership with Japanese company Daiichi Sankyo. The Anglo-Swedish pharmaceutical company said Monday that the treatment's approval was based on results from a Phase III trial,
AstraZeneca's Enhertu gets additional FDA approval
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's (OTCPK:DSKYF) drug Enhertu has been approved by the FDA for the treatment of certain breast cancer patients. Enhertu was approved for the treatment of unresectable or metastatic HR-positive,
19h
on MSN
Berenberg maintains Buy rating on AstraZeneca with GBP140 target
Investors are awaiting the company's fourth-quarter results, scheduled for February 6, for an update on the China issue.
BioSpace
16h
AstraZeneca, Daiichi Sankyo Continue ADC Rally With Enhertu Expansion
Enhertu’s label expansion comes on the heels of the FDA’s approval of the partners' Datroway for a related type of breast ...
4d
‘I was desperate for the AstraZeneca vaccine to succeed. Then I became alarmed by what I saw’
Haematologist Dr Sue Pavord was one of the jab’s biggest supporters, but she knew something was wrong when she saw the ...
1d
AstraZeneca PLC ADR rises Monday, outperforms market
The AstraZeneca PLC ADR AZN rallied 1.48% to $70.08 Monday, on what proved to be an all-around mixed trading session for the ...
Zawya
19h
AstraZeneca achieves top rankings as Best Place to Work across North Africa and Levant in 2024
AstraZeneca, a leading multinational pharmaceutical and biotechnology company, has been recognized as the second-best place ...
4d
AstraZeneca To Pump $570 Million Into Canada, Driving Expansion, Job Growth
AstraZeneca invests $570 million in Canada, expands facilities, and boosts R&D efforts, aiming to deliver 20 new medicines ...
The Manila Times on MSN
2d
AstraZeneca wants to do clinical trials in PH – Roque
MULTINATIONAL pharmaceutical firm AstraZeneca (AZ) wants to conduct the majority of its clinical trials in the Philippines, ...
1d
AstraZeneca rises Monday, outperforms market
Shares of AstraZeneca PLC AZN rallied 1.18% to £111.80 Monday, on what proved to be an all-around positive trading session ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Canada
Daiichi Sankyo
Enhertu
Ontario
Philippines
Feedback